Expansion demonstrates company's commitment to innovation and leadership in global public health
Sanofi is investing €350 million for the construction of a new state-of-the-art vaccine manufacturing facility at the Sanofi Pasteur Canadian headquarters in Toronto, Ontario.
The investment bolsters the company's Canadian operations and its commitment to advancing public health around the world.
The announcement will be made during an event today at Sanofi Pasteur's Toronto facility.
Attendees will include the Honourable Navdeep Bains, Minister of Innovation, Science and Economic Development, Government of Canada, the Honourable Steven Del Duca, Minister of Economic Development and Growth, Government of Ontario, and members of Sanofi's executive leadership.
"Canada has a strong legacy in the research and development of vaccines. With this investment, Sanofi is renewing our longstanding commitment to making Canada central in our effort to protect and improve human health across the globe," said David Loew, Executive Vice President and Head of Sanofi Pasteur.
"Vaccines save three million lives every year and this new facility will take us one step closer to a world where no one suffers or dies from a vaccine-preventable disease."
The new facility will allow Sanofi Pasteur, the vaccines global business unit of Sanofi, to meet the growing demand of five-component acellular pertussis (5-acP) antigen.
Upon completion in 2021, the new building will also be equipped to produce the antigens used in the diphtheria and tetanus vaccines.
"This project is one of the most important investments for the Sanofi global industrial network," said Philippe Luscan, Executive Vice President, Global Industrial Affairs, Sanofi.
"It demonstrates our continued commitment to manufacturing excellence and to better serving our vaccines portfolio to people all over the world."